Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 7/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 3/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14280683 | 0.71 | OPRM1 (0.57) | CXCR4MEN1KMT2AACHEDRD4 | |
| SCHEMBL14280698 | 0.67 | OPRL1 (0.76) | MEN1KMT2ADRD4OPRM1OPRK1 | |
| SCHEMBL15861169 | 0.65 | KMT2A (0.44) | MEN1KMT2AACHEALDH1A1ATM | |
| SCHEMBL14280681 | 0.64 | OPRM1 (0.79) | MEN1KMT2AALDH1A1OPRM1OPRK1 | |
| SCHEMBL17283371 | 0.62 | OPRM1 (0.61) | OPRM1OPRK1OPRL1 | |
| SCHEMBL4880602 | 0.62 | OPRM1 (0.75) | OPRM1OPRK1OPRL1 | |
| SCHEMBL14280678 | 0.62 | OPRM1 (0.44) | MEN1KMT2AALDH1A1ATMOPRM1 | |
| SCHEMBL2598045 | 0.60 | HTR2C (0.41) | — | |
| SCHEMBL1804818 | 0.60 | HTR2C (0.41) | — | |
| SCHEMBL1804819 | 0.60 | HTR2C (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015214-A1 | 3-PIPERIDIN-4-YL-INDOLE ORL-1 RECEPTOR MODULATORS | OGFRL1, OPRL1, ORMDL3 | CXCR4 440/4885MEN1 4352/4885KMT2A 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.